First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults.

Liu, Jingrui; Zhu, Xiaoxue; Zhang, Hong; Wei, Haijing; Yang, Deming; Xu, Zhongnan; Huo, Dandan; Li, Xiaojiao; Ding, Yanhua

Liu, Jingrui; Zhu, Xiaoxue; Zhang, Hong; Wei, Haijing; Yang, Deming; Xu, Zhongnan; Huo, Dandan; Li, Xiaojiao; Ding, Yanhua.

Afiliación

Liu J; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Zhu X; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Zhang H; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Wei H; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Yang D; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Xu Z; Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Huo D; Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Li X; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Ding Y; Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.

Front Pharmacol ; 12: 689523, 2021.

Article en En | MEDLINE | ID: mdl-34366847

Palabras clave

TQ-F3083; pharmacodynamics; pharmacokinetics; phase I; type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google